EA201071422A1 - Способы лечения заболеваний, связанных с мейотическим кинезином - Google Patents
Способы лечения заболеваний, связанных с мейотическим кинезиномInfo
- Publication number
- EA201071422A1 EA201071422A1 EA201071422A EA201071422A EA201071422A1 EA 201071422 A1 EA201071422 A1 EA 201071422A1 EA 201071422 A EA201071422 A EA 201071422A EA 201071422 A EA201071422 A EA 201071422A EA 201071422 A1 EA201071422 A1 EA 201071422A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- meiotic
- kinase
- hset
- diseases associated
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5759008P | 2008-05-30 | 2008-05-30 | |
| PCT/US2009/045406 WO2009155025A1 (en) | 2008-05-30 | 2009-05-28 | Methods of treating a meiotic kinesin-associated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201071422A1 true EA201071422A1 (ru) | 2011-08-30 |
Family
ID=41110533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201071422A EA201071422A1 (ru) | 2008-05-30 | 2009-05-28 | Способы лечения заболеваний, связанных с мейотическим кинезином |
Country Status (12)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486449B2 (en) | 2007-10-09 | 2016-11-08 | Malka COHEN-ARMON | Cancer therapy |
| MX2010012931A (es) | 2008-05-30 | 2011-02-24 | Dana Farber Cancer Inst Inc | Metodos para tratar una enfermedad asociada con quinesina meiotica. |
| WO2013142817A2 (en) | 2012-03-23 | 2013-09-26 | Dennis Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| US20150309031A2 (en) * | 2013-12-05 | 2015-10-29 | Novazoi Theranostics | Compositions and methods for prognosis and treatment of cancer |
| WO2015130953A1 (en) * | 2014-02-28 | 2015-09-03 | Novazoi Theranostics, Inc. | Method for determining the risk profile of neoplastic tissue |
| CN113456633A (zh) * | 2021-06-11 | 2021-10-01 | 广西医科大学 | 红海海绵素a在制备抗肺癌侵袭转移药物中的应用 |
| AU2023205435A1 (en) | 2022-01-10 | 2024-08-22 | Cancer Research Horizons | Substituted heterocycles as hset inhibitors |
| CN115327125A (zh) * | 2022-07-14 | 2022-11-11 | 宁波大学 | 一种蛋白质inf2在制备肝癌诊断标志物中的应用 |
| CN120265629A (zh) | 2022-11-07 | 2025-07-04 | 默克专利股份公司 | 被取代的双环和三环hset抑制剂 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| AU4367700A (en) * | 1999-04-20 | 2000-11-02 | Cytokinetics, Inc. | Human kinesins and methods of producing and purifying human kinesins |
| US6410254B1 (en) * | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US7202051B1 (en) * | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US7416856B2 (en) * | 1999-05-18 | 2008-08-26 | Cytokinetics, Inc. | High sensitivity assay for detection of nucleoside diphosphate production |
| US6743599B1 (en) * | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| WO2002078639A2 (en) | 2001-03-29 | 2002-10-10 | Bristol-Myers Squibb Company | A method of treating proliferative diseases using eg5 inhibitors |
| US20040009156A1 (en) * | 2001-10-12 | 2004-01-15 | Christoph Reinhard | Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
| US7163927B2 (en) | 2002-05-23 | 2007-01-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
| US20050100508A1 (en) | 2003-11-12 | 2005-05-12 | Nichols M. J. | Methods for identifying drug combinations for the treatment of proliferative diseases |
| US20070026424A1 (en) * | 2005-04-15 | 2007-02-01 | Powell Charles A | Gene profiles correlating with histology and prognosis |
| AR062200A1 (es) | 2006-08-04 | 2008-10-22 | Aeterna Zentaris Gmbh | Derivados de antraceno y su uso para el tratamiento de emfermedades tumorales bengnas y malingnas |
| US20080051463A1 (en) * | 2006-08-04 | 2008-02-28 | Aeterna Zentaris Gmbh | Anthracene compounds and their use for treating benign and malignant tumor disorders |
| WO2008132752A2 (en) | 2007-05-01 | 2008-11-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for predicting cancer metastasis |
| MX2010012931A (es) | 2008-05-30 | 2011-02-24 | Dana Farber Cancer Inst Inc | Metodos para tratar una enfermedad asociada con quinesina meiotica. |
-
2009
- 2009-05-28 MX MX2010012931A patent/MX2010012931A/es not_active Application Discontinuation
- 2009-05-28 US US12/994,920 patent/US8629118B2/en active Active
- 2009-05-28 BR BRPI0912043-2A patent/BRPI0912043A2/pt not_active IP Right Cessation
- 2009-05-28 WO PCT/US2009/045406 patent/WO2009155025A1/en not_active Ceased
- 2009-05-28 EP EP09767337.0A patent/EP2315594B1/en active Active
- 2009-05-28 EA EA201071422A patent/EA201071422A1/ru unknown
- 2009-05-28 ES ES09767337.0T patent/ES2633930T3/es active Active
- 2009-05-28 CA CA 2725911 patent/CA2725911A1/en not_active Abandoned
- 2009-05-28 AU AU2009260527A patent/AU2009260527A1/en not_active Abandoned
- 2009-05-28 CN CN2009801299003A patent/CN102316877A/zh active Pending
- 2009-05-28 KR KR20107029850A patent/KR20110022000A/ko not_active Withdrawn
- 2009-05-28 JP JP2011511802A patent/JP5735417B2/ja not_active Expired - Fee Related
-
2013
- 2013-12-11 US US14/103,520 patent/US8962592B2/en not_active Expired - Fee Related
-
2015
- 2015-01-07 US US14/591,678 patent/US9645136B2/en not_active Expired - Fee Related
- 2015-02-04 JP JP2015020184A patent/JP6132409B2/ja not_active Expired - Fee Related
-
2016
- 2016-05-31 JP JP2016108400A patent/JP6184556B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20150111786A1 (en) | 2015-04-23 |
| US8629118B2 (en) | 2014-01-14 |
| JP5735417B2 (ja) | 2015-06-17 |
| CN102316877A (zh) | 2012-01-11 |
| CA2725911A1 (en) | 2009-12-23 |
| WO2009155025A1 (en) | 2009-12-23 |
| ES2633930T3 (es) | 2017-09-26 |
| JP2015131813A (ja) | 2015-07-23 |
| US20140106344A1 (en) | 2014-04-17 |
| BRPI0912043A2 (pt) | 2019-09-24 |
| EP2315594B1 (en) | 2017-05-17 |
| US9645136B2 (en) | 2017-05-09 |
| JP2011525174A (ja) | 2011-09-15 |
| AU2009260527A1 (en) | 2009-12-23 |
| US20110190374A1 (en) | 2011-08-04 |
| JP2016169224A (ja) | 2016-09-23 |
| JP6132409B2 (ja) | 2017-05-24 |
| MX2010012931A (es) | 2011-02-24 |
| US8962592B2 (en) | 2015-02-24 |
| JP6184556B2 (ja) | 2017-08-23 |
| EP2315594A1 (en) | 2011-05-04 |
| KR20110022000A (ko) | 2011-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| PH12020552135A1 (en) | Kdm1a inhibitors for the treatment of disease | |
| EA201390550A1 (ru) | Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях | |
| MX2009011226A (es) | Inhibidores especificos pdgfrbeta. | |
| EP3208615A3 (en) | Uses of labeled hsp90 inhibitors | |
| PH12012501581A1 (en) | Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors | |
| CY1115076T1 (el) | ΕΝΑ ANTΙ-PDGFRα ΑΝΤΙΣΩΜΑ ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΜΕΤΑΣΤΑΤΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΩΝ ΟΣΤΩΝ | |
| GT200800202A (es) | Quinazolinas para la inhibicion de pdk1 | |
| EP3311818A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
| EA201690994A1 (ru) | Антагонисты активина-actriia и применение для стимуляции роста кости у больных раком | |
| EA200900819A1 (ru) | Хиназолины для ингибирования pdk1 | |
| EA201201464A1 (ru) | Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний | |
| EP3722810A3 (en) | Molecular profiling of tumors | |
| EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
| WO2011112953A3 (en) | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers | |
| EA200700321A1 (ru) | Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы | |
| MX361467B (es) | Compuestos de isoindolina para uso en el tratamiento de cancer. | |
| NZ590550A (en) | Inhibitors of Apoptosis (IAP) for treating cancer | |
| BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
| EA201100874A1 (ru) | Соединения для лечения рака | |
| ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
| DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
| NZ592326A (en) | Erbb-3 (her3)-selective combination therapy | |
| ATE410155T1 (de) | Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung | |
| UA100545C2 (ru) | Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт |